Alice Blue Home
URL copied to clipboard

Trending News

Sun Pharma gets DCGI nod to launch generic semaglutide in India

Sun Pharmaceutical Industries Limited received DCGI approval to manufacture and market generic semaglutide injection, Noveltreat, in India for chronic weight management after patent expiry.
Sun Pharma research laboratory with scientist conducting experiments

Introduction

Leading pharmaceutical company received DCGI approval to manufacture and market generic semaglutide injection, Noveltreat, for chronic weight management in adults after patent expiry in India.

Alice Blue Image

Also Read: Ceinsys Tech stock rallies 5% after bagging ₹12.21 Cr municipal work order

Share price movement of Sun Pharma

On January 23, 2026, Sun Pharmaceutical Industries Limited opened at ₹1,640.15, up 0.35% from its previous close of ₹1,634.40. The stock reached a high of ₹1,640.20 (0.36%) and a low of ₹1,625.30. By 11:30 AM, it traded at ₹1,631.30, a -0.19% decrease, with a market cap of ₹3,91,394.29 crore.

Sun Pharma Receives DCGI Approval for Generic Semaglutide Injection

Sun Pharmaceutical Industries Limited received approval from the DCGI to manufacture and market generic semaglutide injection in India for chronic weight management in adults.

The product, named Noveltreat, will launch after the expiry of semaglutide patent. It follows a Phase III clinical trial conducted in India. Five dose strengths will be available.

Noveltreat is administered via a prefilled pen with weekly maintenance dose of 2.4 mg. Sun Pharma had earlier received approval for semaglutide for type 2 diabetes under the brand Sematrinity.

Stock performance of Sun Pharma for Period of 1 week, 6 months, and 1 year

Sun Pharmaceutical Industries Limited delivered a -2.08% return over the past week, declined by -3.81% in the past 6 months, and fell -10.9% over the past 1 year.

Alice Blue Image

Also Read: Cupid Ltd jumps 6% as company to invest ₹331.53 Cr in Baazar Style Retail, know why

Shareholding pattern of Sun Pharma

ParticularsDec 2025Sep 2025Jun 2025
Promoter54.50%54.50%54.50%
FII16.10%16.60%17.30%
DII20.80%20.20%19.50%
Public9%9%8.50%

About Sun Pharma

Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) is India’s largest pharmaceutical company, manufacturing and marketing branded and generic formulations, APIs, with global facilities and operations across international markets.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs

Q: Why is Sun Pharmaceutical Industries Limited share price rising today?

A: Sun Pharmaceutical Industries Limited received DCGI approval to manufacture and market generic semaglutide injection, Noveltreat, for chronic weight management in India.

Q: What is Sun Pharmaceutical Industries Limited’s main business focus?

A: Sun Pharmaceutical Industries Limited manufactures, develops, and markets branded and generic formulations and Active Pharma Ingredients (APIs) globally.

Q: What is the 52-week high and low of Sun Pharmaceutical Industries Limited stock?

A: Sun Pharmaceutical Industries Limited stock’s 52-week high is ₹1,850.95 and the 52-week low is ₹1,547.25.

Submit the form, and get to know how you scored!!!

Gainers & Losers

Read More News
गिफ्ट निफ्टी लाइव टुडे अक्टूबर 12: कच्चे तेल की कीमतों में गिरावट से बाजार में तेजी के संकेत
Global Market

गिफ्ट निफ्टी लाइव टुडे अक्टूबर 12: कच्चे तेल की कीमतों में गिरावट से बाजार में तेजी के संकेत

मेटा डिस्क्रिप्शन: गिफ्ट निफ्टी लाइव टुडे अक्टूबर 12 के संकेतों से भारतीय बाजारों में सकारात्मक शुरुआत की उम्मीद है। कच्चे

*T&C apply